Cocrystal Pharma (NASDAQ:COCP) Releases Earnings Results, Hits Expectations

Cocrystal Pharma (NASDAQ:COCPGet Rating) issued its earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04), MarketWatch Earnings reports.

COCP opened at $0.38 on Friday. The business has a 50 day moving average of $0.51 and a 200-day moving average of $0.63. Cocrystal Pharma has a 52 week low of $0.37 and a 52 week high of $1.49.

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in Cocrystal Pharma by 43.4% during the 3rd quarter. Geode Capital Management LLC now owns 800,602 shares of the company’s stock valued at $840,000 after acquiring an additional 242,270 shares during the period. LPL Financial LLC increased its stake in shares of Cocrystal Pharma by 12.2% during the fourth quarter. LPL Financial LLC now owns 200,250 shares of the company’s stock valued at $130,000 after purchasing an additional 21,750 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Cocrystal Pharma by 14.3% during the third quarter. Goldman Sachs Group Inc. now owns 157,952 shares of the company’s stock valued at $166,000 after purchasing an additional 19,784 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Cocrystal Pharma in the 3rd quarter worth approximately $143,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Cocrystal Pharma in the 2nd quarter worth approximately $137,000. Institutional investors own 15.43% of the company’s stock.

COCP has been the topic of a number of analyst reports. Noble Financial restated a “buy” rating and issued a $5.00 price objective on shares of Cocrystal Pharma in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Cocrystal Pharma in a research report on Monday, March 14th.

About Cocrystal Pharma (Get Rating)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

Recommended Stories

Earnings History for Cocrystal Pharma (NASDAQ:COCP)

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.